The efficiency of various laboratory and radiological investigations in the differentiation of ectopic from pituitary dependent Cushing's syndrome was studied, based on findings in 23 patients with verified Cushing's disease and seven patients with the ectopic ACTH syndrome.
INTRODUCTION
Following the identification of Cushing's syndrome, the differential diagnosis of the broad group that are ACTH driven from the smaller group caused by a cortisol-secreting adrenal tumour is relatively easy [1] . Real difficulty arises in the distinction between an ACTHsecreting pituitary adenoma (Cushing's disease) and an ACTH secreting tumour which is located ectopically. The results of surgical management of an ectopic group of patients have been discussed by our team in an initial report [2] . Subsequently, Howlett et al. [3] presented a systematic account of a series which compared the results of investigations obtained from a pituitary-driven group in contrast to an ectopic group, to which they added further studies later [4] .
We now report our findings from conventional tests, based on 23 patients with pituitarydriven Cushing's disease, all confirmed by cure of the disease by pituitary ablative treatment, in comparison with seven patients with histologically confirmed ectopic sources of ACTH.
PATIENTS AND METHODS
Two groups of adult patients were studied. The first comprised 23 patients with hitherto untreated Cushing's disease who were investigated and treated consecutively in our unit with interstitial pituitary irradiation during the period 1971 to 1982, and followed up by ourselves into full biochemical and clinical remission [5] . The second group comprised seven patients also presenting with obvious Cushing's syndrome, and who were found to have histologically identifiable ectopic ACTH-producing tumours; they were studied in the period 1967 to 1987.
All patients in both groups had previously been shown to have elevated serum cortisol concentrations with a loss of diurnal variation, measurable plasma ACTH levels, and high urine free cortisol concentrations. All but one were ambulant when studied. (Table 1) All but one of the 23 patients were female and were aged 18-60 years. The length of history, based on the time when symptoms were first noticed up to the time of presentation to our unit, ranged from 12 to 72 months (mean 40 months). Pituitary fossa radiology by plain coned views and by lateral hypocycloidal tomography (3 mm cuts) was performed in all 23 patients; 10 were abnormal. Pituitary CT scan was performed in the later cases ( Patients 6, 13 and 14) : this showed the presence of a tumour in Patient 13; Patients 6 and 14 had normal CT scans. The diagnosis of adenoma was confirmed by pituitary histology in all 11 patients with adequate biopsies. The period of follow-up since referral has ranged from 3 to 13 years (159 patient-years) with no recurrence of disease in any patient. (Table 2) Seven patients with histologically proven ectopic sources of ACTH were aged 23 to 59 years (mean 38 years) at presentation to us. Only one patient was female and her case has been reported in detail [6] . The length of history at presentation to us ranged from 2 to 12 months (mean 7.4 months). There were already clinical signs of an underlying tumour in four: Patients B, C and E had irregular hepatomegaly consistent with metastases, and this was Table 2 . 6 The only male.
CLINICAL FEATURES, RADIOLOGY, AND HISTOPATHOLOGY

Cushing's Disease Group
Ectopic ACTH Group
confirmed radiologically by liver scan or angiogram, while Patient G had clinical and radiological evidence of metastatic spread of a previously treated medullary carcinoma of the thyroid. In Patients A and D, plain chest radiographs and tomograms showed a lung mass consistent with a bronchial carcinoid. In Patient F, an ectopic nature was suspected on the grounds of his biochemical tests, but there was no clinical or radiological clue as to the site of the ACTH source, and the appendicular carcinoid was found only at abdominal exploration. Some data pertaining to six of our ectopic group have been reported by Davies et al. [2] . Our Patients A.B.C, D, E, F, are those referred to before as Patients2, 3, 4, 10, 9, 8 . Our Patient E was reported by Ghatei et al. [7] in considerable biochemical detail.
BIOCHEMICAL METHODS
Blood was taken for plasma potassium from each patient on several occasions before any diuretic or potassium therapy, and the mean is given. Blood glucose was measured on venous whole blood by the ferricyanide autoanalyser method in the first 14 patients, and as plasma glucose with the glucose oxidase method in the remaining 16. Fasting samples were taken from all patients, the upper limit of normal adopted being 90 mg/dl for blood glucose or 6 mmol/1 for plasma glucose. Oral glucose tolerance testing was performed using 50 g glucose, with an abnormal test being said to occur when the peak level attained exceeded 160 mg/dl for blood glucose or 10 mmol/1 for plasma glucose, together with a 2 hour value exceeding 120 mg/dl blood glucose or 7.1 mmol/1 plasma glucose [8] . Any patient showing an elevated fasting glucose and/or an abnormal glucose tolerance test has been reported in Tables 3 and 4 as having impaired glucose tolerance [9] .
B. Blunt and others
Serum cortisol concentrations were obtained at 9.00 a.m. and midnight. A competitive protein binding method [10, 11] was used in all but Patient G, with an upper limit of normal at 9.00 a.m. of 700 nmol/1 and at midnight of 200 nmol/1. Details of how the normal ranges were established have been reported earlier [11, 12] . All of our patients, except Patient G, were ambulant at the time of testing. The effect of corticosterone on the assay was quantitated and found to be small, therefore its contribution to cortisol readings was not taken into account. Nevertheless, the cortisol reading is within ± 12 per cent of true cortisol levels as shown by chromatographic methods [10] . Serum cortisol levels in Patient G were measured by a solid phase first antibody radioimmunoassay [13] . Intra-and interassay coefficients of variation were 6.5 per cent and 9.8 per cent respectively at a cortisol value of 447 nmol (NR<700 nmol/1 at 9.00 a.m.; <250 nmol/1 at midnight). No samples were measured by the Mattingly method in this series.
Plasma for determination of ACTH levels was taken at 9.00 a.m. and midnight and was measured by double antibody radioimmunoassay after extraction onto vycor glass [14] . The normal range at 9.00 a.m. is 10-80 ng/1 and at midnight < 10 ng/1. The interassay coefficient of variation is 10.9 percent at 123 ng/1. Urinary free (unconjugated) cortisol was measured by competitive protein binding [10] , the upper limit of normal being 270 nmol/24 hours [15] with a mean of 100 nmol/24 hours. The method is also sensitive to 11 -deoxycortisol and corticosterone which give an effect that is 90 per cent and 70 per cent of that of cortisol respectively. The quantities of these two steroids are usually small. The average deviation from values obtained by chromatographic methods for cortisol was ± 13 per cent (p< 0.001) [10] .
Urine 17-oxogenic steroids and 17-oxosteroids were determined by the method of Appleby et al. [16] in all cases. The upper limits of normal are 60 /*mol/24 hours, and 77 mol/24 hours, respectively [16, 17] . Serum 11-deoxycortisol ('compound S') measurements were made by a competitive protein binding method in all cases except Patient G. The CPB method for 11-deoxycortisol was an adaptation of the method used for determination of unbound cortisol [10] , and involved an additional extraction onto carbon tetrachloride, which was then dried and assayed as for urine free cortisol. The cross-reactivity of cortisol in this assay was 1.3 per cent and our basal range is 28-84 nmol/1. Serum 11-deoxycortisol measurements in Patient G were made by a direct non-extraction double antibody radioimmunoassay (Radioimmunoassay Systems Laboratories Inc., California, USA). The intra-and interassay coefficients of variation were 5.9 per cent and 13.7 per cent respectively, at a level of 8.4 nmol/1; crossreactivity with cortisol is 1.4% The normal range (basal) is <23 nmol/1.
DYNAMIC TESTS
High Dose Dexamethasone Suppression Test
Dexamethasone 2 mg was administered 6 hourly for 72 hours. Basal collections of blood at 9 a.m. and midnight for cortisol, and urine for 17-oxogenic steroids, 17-oxosteroids and unbound cortisol were made on two consecutive 24-hour periods immediately prior to the test, and on the second and third days on dexamethasone. The extent of suppression of each parameter was calculated as the percentage change of the mean values found on days 2 and 3 on dexamethasone, compared with the mean basal value. Suppression by 50 per cent or more of urine 17-hydroxy corticosteroids levels (equivalent to 17-oxogenic steroids) is said to be diagnostic of Cushing's disease rather than an adrenal tumour [18, 19] , and will be adopted here as a criterion of suppression.
Metyrapone Stimulation Test
Metyrapone was given at a dose of 750 mg 4-hourly for 24 hours, commencing at 9 a.m. Twenty-four hour urine collections of 17-oxogenic steroids (and 17-oxosteroids) were made on the day of metyrapone administration and on the day after metyrapone. Blood for 11-deoxycortisol levels was taken at 9 a.m. on the morning just before starting metyrapone, and at 9 a.m. the next day. A positive response to metyrapone was recorded when there was an increase of 100 per cent or more of 11 -deoxycortisol or urine 17-oxogenic steroids [ 18] either on the day of metyrapone, or the day after, compared with their basal values.
STATISTICAL METHODS
Student's unpaired /-test was used for the comparisons of all values between the two groups. The x 1 test was used for comparison of the blood sugar data, and for the analysis of the responses to combined dexamethasone suppression and metyrapone stimulation.
RESULTS
BASAL BIOCHEMICAL DATA (Tables 3 and 4)
Plasma Potassium
In the 23 patients with Cushing's disease, levels ranged from 3.5 to 4.5 mmol/1 with a mean of 3.9 mmol/1; four patients (17 per cent) showed marginally subnormal levels (< 3.8 mmol/1). All seven patients with ectopic ACTH production had hypokalaemia (range 1.7-2.8 mmol/1, mean 2.2 mmol/1). The difference between the two groups was highly significant (p < 0.0001). If the two groups are compared in relation to a reference level of 3.0 mmol/1, there is no overlap between the groups.
Plasma Bicarbonate
Levels ranged from 24 to 35 mmol/1 in the Cushing's disease group (mean 29 mmol/1), compared with a range of 32-44 mmol/1 (mean 37 mmol/1) in the ectopic group (p < 0.0001). In relation to a reference level of 30 mmol/1, a distinction, with two marginal exceptions, (Patients 1 and 77, Table 3 ) is seen between the two groups.
Glucose Tolerance
This was abnormal in five of the 23 patients with Cushing's disease (21 per cent) compared with four of seven in the ectopic group (57 per cent) (•/} = 3.18; p = 0.087).
Basal 9 a.m. Serum Cortisol
Values obtained under basal conditions were above the upper limit of normal (700 nmol/1) in only two patients with Cushing's disease (Patients 2 and 18). The range of values found in this group (303-1173 nmol/1), was almost entirely outside the range of values found in patients with the ectopic ACTH syndrome (828-2159 nmol/1). The overlap was due to one patient (Patient 18) in the Cushing's disease group who had unusually high 9 a.m. (and midnight) values. The other 22 patients with Cushing's disease (96 per cent) had 9 a.m. serum cortisol values below a reference level of 800 nmol/1, whereas all seven patients with ectopic ACTH production had values greater than this. The difference between the mean values of the two groups (576 nmol/1 and 1460 nmoi/1) was highly significant (p< 0.001).
Basal Midnight Serum Cortisol
Values were elevated (> 200 nmol/1) in all patients in both groups. The range found in the Cushing's disease group (321-1048 nmol/1) was almost completely outside that found in the ectopic group (800-1515 nmol/1). The overlap was again due to the high value in Patient 18 in the Cushing's disease group. The remaining 22 patients in this group had midnight values below a reference level of 800 nmol/1, whereas all seven with the ectopic ACTH syndrome had values greater than this. The mean values for the two groups of 519 nmol/1 and 1117 nmol/1 were significantly different (/?<0.0001).
Combined Basal 9 a.m. and Midnight Serum Cortisol
Elevation of serum cortisol at both 9 a.m. and midnight to above a reference level of 800 Tables 3 and 4 
Basal 17-oxogenic Steroids and 17-oxosteroids
DYNAMIC TESTS
High Dose Dexamethasone Suppression Test
This was performed on all 30 patients, with evaluations available of the responses of at least two of the following four measurements: 9 a.m. and midnight serum cortisol (taken as a single parameter), urinary free cortisol, 17-oxogenic steroids and 17-oxosteroids. The Tables  5 and 6 . The mean suppression of 9 a.m. serum cortisol was 58 per cent for Cushing's disease, and 28 per cent for the ectopic group (p < 0.002). Five of the seven patients in the ectopic group showed less than 50 per cent suppression (an empirically chosen reference point), compared with eight of the 19 patients with Cushing's disease.
The mean suppression of midnight serum cortisol was 64 per cent for the Cushing's disease group, and 41 per cent for the ectopic group (p = 0.09); there was substantial overlap. Three of the five patients in the ectopic group suppressed by less than 50 per cent compared with four of the 17 patients tested in the Cushing's disease group.
When the extent of suppression was expressed as a mean of the 9 a.m. and midnight percentage changes from basal values, there was some overlap in range of values found in the two groups, and the difference between their means was not significant (p = 0.063). Suppression of the mean value by 50 per cent occurred in nine of the 20 patients with Cushing's disease, and four of the five with ectopic ACTH.
The mean of the absolute values for the 9 a.m. and midnight cortisol was calculated for each patient, and then the means for each group were compared. A mean suppressed value of 222 nmol/1 in the Cushing's disease group was considerably lower (p < 0.0001) than the value of 651 nmol/1 in the ectopic group (Fig. 1) . There was no overlap in their ranges. None of 23 patients with Cushing's disease exceeded a reference value of 450 nmol/1 on dexamethasone, whereas all of five ectopic cases did so.
The suppression of urinary free cortisol in the Cushing's disease group was 71 per cent compared with a mean suppression of only 6 per cent in the ectopic group (p< 0.0001). All but five of the 21 patients with Cushing's disease achieved 50 per cent reduction in unbound cortisol while only one of the ectopic group did so. The importance of the apparent suppression of urinary free cortisol found in this patient (Patient C) is difficult to evaluate, as his basal unbound cortisol levels had shown marked spontaneous fluctuation (from 1394 to 6637 nmol/24 hours).
The mean suppressed value (Fig. 1) in the Cushing's disease group was 246 nmol/24 hours, compared with 9641 nmol/24 hours in the ectopic group (p< 0.009). None of 21 patients with Cushing's disease exceeded a reference value of 1000 nmol/24 hour while on dexamethasone, while all five ectopic cases did so.
There was a highly significant difference (p< 0.0001) in the mean suppression of urinary 17-oxogenic steroids between the two groups: 70 per cent suppression for the Cushing's disease group compared with 22 per cent for the ectopic group. All 18 patients with over 50 per cent suppression had Cushing's disease. The one patient (Patient A) from the ectopic group who showed impressive suppression for 17-oxogenic steroids (but < 50 per cent) also showed > 50 per cent suppression of both the 9 a.m. and the midnight serum cortisol. He had otherwise performed as expected, with severe hypokalaemic alkalosis and extremely high basal levels of serum cortisol and urinary steroids. Three of the Cushing's disease group failed to show suppression of 50 per cent.
There was marked overlap between the two groups in extent of suppression of urinary 17-oxogenic steroids: mean suppression for the ectopic group was 28 per cent, compared with 50 per cent for the Cushing's disease group (p = QA). However, all 17 patients showing a reduction of > 50 per cent had Cushing's disease. 
Metyrapone Test
This was performed in 22 of the 23 patients with Cushing's disease and in all seven with ectopic ACTH. The absolute values obtained are shown in Table 7 and 8.
There was almost complete overlap between the ranges of percentage change of urine 17-oxogenic steroids seen in the two groups; comparison of their mean values showed no significant difference (p = 0.08). When the 21 patients with Cushing's disease are considered, failure of a ^100 per cent rise occurred in nine, compared with four of the five with ectopic ACTH.
The two groups of patients showed complete overlap in urine 17-oxosteroids. When changes in levels of serum 11-deoxycortisol (measured 24 hours after the first dose of metyrapone) were compared, a difference between the two groups emerged: in the 16 Cushing's disease patients studied, concentrations rose by a mean of 530 per cent, compared with a mean increase of only 80 per cent in the ectopic group (p = 0.06). Values did not at least treble in four of the 16 Cushing's disease patients, or in any of the four patients in the ectopic group. The absolute values of 11-deoxycortisol did not differ between the two groups.
Combination of Dynamic Test Criteria
The response to both dexamethasone and metyrapone for each patient was considered. A patient was deemed to have shown overall suppression by dexamethasone if there was at vs. pituitary-dependent group in Table 7 .
least a 50 per cent suppression of at least two of the four measurements (9.00 a.m. and midnight serum cortisol; urinary free cortisol, 17-oxogenic steroids, and 17-oxosteroids) in the test; overall stimulation in response to metyrapone was deemed to have occurred if there was a ^ 100 per cent increase in both measurements (serum 11-deoxycortisol and urine 17-oxogenic steroids).
In the Cushing's disease group, only one {Patient 16) of the 19 patients (4 per cent) with complete tests showed neither overall suppression in response to dexamethasone, nor overall stimulation to metyrapone. All but one of the seven patients in the ectopic ACTH group (14 per cent), (Patient D, who failed to halve serum cortisol or unbound cortisol, but doubled both 17-oxogenic steroids and 11-deoxycortisol) showed failure of responses to both tests. The two groups clearly differed (j 2 = 15.57, p< 0.0001). Ten of the 19 patients with Cushing's disease in whom both tests were performed responded appropriately to both tests. This contrasts with the ectopic group, where no patient showed overall suppression to dexamethasone according to the above criteria, and only one patient (Patient D) showed overall stimulation to metyrapone.
RADIOLOGY
Radiographs of the Pituitary Fossa
Plain coned radiographs or lateral hypocycloidal tomography of the pituitary fossa showed an abnormal appearance in 10 of the 23 patients (48 per cent) with Cushing's disease. No abnormality was found in the seven patients with ectopic ACTH.
Computerized Tomography
CT scans of the pituitary were also performed in the last three patients (Patients 6,13, and 14) in the Cushing's disease group, one of whom (Patient 13) had appearances, both on CT and plain films, consistent with the presence of a tumour; the two patients whose CT scans were normal also had normal plain radiographs, although case 14 had an adenoma shown on biopsy.
Other Radiography
In six of the seven patients with ectopic ACTH, the location of the primary tumour, or of its metastases was established by relatively non-invasive radiology. Thus, plain chest films revealed abnormal shadows in Patients A, D and G, confirmed on tomography; in Patients A and D the masses represented a bronchial carcinoid, and in Patient G, metastatic deposits from a known medullary carcinoma of the thyroid. In Patients B, CandE the clinical finding of hepatomegaly was investigated by liver scan or angiogram, and this confirmed the presence of metastatic deposits. Liver biopsy in Patients C, D and E established the histological diagnoses shown in Table 2 . Patient Fhad no clinical or radiological features to suggest the site of the ACTH-producing tumour. An anterior approach for bilateral adrenalectomy was planned. At operation the appendicular carcinoid responsible for his Cushing's syndrome was revealed and removed. Barium studies had previously been normal. Complete and permanent cure was obtained.
VENOUS SAMPLING FOR ACTH LEVELS
Venous sampling for ACTH gradients at various sites, including high internal jugular veins, was performed on Patients C, D, and E with ectopic ACTH production. In Patient C (pancreatic apudoma and liver metastases), venous sampling at laparotomy revealed a minimal step-up in ACTH concentrations from the aortic blood to the venous blood draining the pancreatic tumour (878 pg/ml compared with 1070 pg/ml) whereas a 1.5 times increase is expected for it to be significant [20] . In Patient D (bronchial carcinoid), no ACTH gradient was found despite sampling from high and low internal jugular vein sites, right and left subclavian veins, SVC above the right atrium and FVC below it. In Patient E (apudoma with liver metastases, primary unknown), total body venous sampling for ACTH revealed the highest concentration in the right hepatic vein, which was consistent with metastases, but unhelpful regarding the site of the primary tumour.
CONSIDERATION OF REFERENCE CRITERIA Table 9 summarizes the results of all the criteria proposed from this study to distinguish between Cushing's disease and the ectopic ACTH syndrome. Criteria which are most in favour of an ectopic cause (p< 0.001 at least) are: male sex, history < 18 months; hypokalaemic alkalosis, basal serum cortisol (at both 9 a.m. and midnight) > 800 nmol/1; midnight ACTH > 100 ng/1; unbound cortisol > 1300 nmol/24 hours; suppression on high dose dexamethasone suppression test of 17-oxogenic steroids by < 50 per cent and urinary free cortisol on dexamethasone of > 1000 nmol/24 hours; and a mean of 9 a.m. and midnight serum cortisol on dexamethasone of >450 nmol/1. Failure to respond to both dexamethasone or metyrapone is also a strong indication of ectopic disease.
DISCUSSION
In this investigation of patients showing obvious Cushing's syndrome, a number of clinical features, basal and dynamic biochemical tests (summarized in Table 9 ), radiology and histology have been assessed as discriminants between pituitary-driven or ectopic ACTH syndrome.
Of the clinical features, the length of history (mean 40 months in Cushing's disease compared with 7.4 months in the ectopic group; p < 0.0001) and the sex of the patient (96 per cent of Cushing's disease patients were female compared with 14 per cent in the ectopic group) appeared to be good discriminants.
In confirmation of the results of others [3] , the plasma potassium concentration was found to be a reliable pointer, with a value < 3.0 mmol/1 being highly suggestive of an ectopic cause. Glucose intolerance was a poor discriminant.
A comparison between the two groups in respect of the basal 9 a.m. or midnight serum cortisol levels revealed an almost complete demarcation; a value at either or both sampling times greater than 800 nmol/1 is highly suggestive (only one error) of an ectopic source of ACTH, and also the difference in mean values for the two groups was highly significant (p< 0.001). However, the usefulness of basal serum cortisol levels has been questioned by Howlett el al. [3] , who found considerable overlap between ectopic patients and those with Cushing's disease using mean values of plasma cortisol obtained from six samples over two days.
In our study there was a substantial overlap between the two groups in respect of the ACTH level at either 9 a.m. or midnight. In agreement with the findings reported elsewhere [3, 21] we suggest that plasma ACTH measurements are of limited discriminating use, unless values greater than 200 ng/1 at 0900 are found, in which case an ectopic source is highly likely [22] [23] [24] . Basal measurements of UFC showed little overlap between the two groups, values greater than 1300 nmol/24 hours being highly suggestive of an ectopic source of ACTH. In contrast, basal measurements of urine 17-oxogenic steroids and 17-oxogenic steroids were unhelpful, in accord with findings elsewhere [15] , and could be abandoned in this context.
The high-dose dexamethasone suppression test was fairly effective for aetiological diagnosis. Thus, suppression by < 50 per cent in 9 a.m. or midnight serum cortisol, urine free cortisol and 17-oxogenic steroids all pointed to a certain extent to an ectopic source of ACTH. Changes in midnight levels of serum cortisol were not more discriminatory than those at 9.00 a.m. However, combination of the 9.00 a.m. and midnight absolute values produced a mean value which strongly discriminated between the two groups: <450 nmol/1 was invariably found in Cushing's disease, and > 450 n mol/1 was always found in the ectopic syndrome. We can compare our findings from the dexamethasone suppression procedure with those of some other groups. Howlett et al. [3] found that while 91 per cent of their 44 patients with Cushing's disease showed suppression of urine 11-OHCS (measured from 0 to 48 hours and defined as suppression by ^ 50 per cent of the basal value), 33 per cent of nine patients with occult ectopic ACTH also responded in this way; they found that fewer ectopic, but also fewer pituitary cases showed significant suppression of urine 17-oxogenic steroids. Suppression of plasma cortisol by 50 per cent was found in 78 per cent of 46 patients with Cushing's disease compared with 11 per cent of those nine with ectopic ACTH. Grossman et al. [4] report that four of 20 patients with Cushing's disease failed to suppress their serum cortisol by ^ 50 per cent, while none of three ectopic cases did so, which closely accords with our series. Any differences may be due to the fact that we use an extended form of dexamethasone suppression test, using 8 mg per day over 72 hours, and taking samples only on the second and third days, whereas the groups mentioned above performed the test over 48 hours with collection during the first and second days on dexamethasone. Liddle [18] found that it was occasionally necessary to extend the dexamethasone test to 72 hours in order to unveil suppressibility of 50 per cent in patients with Cushing's disease. Nicholls [25] reviewed the literature between 1940 and 1966 concerning steroid tests in the differential diagnosis of Cushing's syndrome and found the dexamethasone procedure to be the most useful in identifying cause, when this was either a pituitary or adrenal tumour. However, as has been the case with many of the series addressing this problem, the number of patients reported with a proven ectopic syndrome are few (for reviews see Crapo [1] and Gold [26] . Subsequently, reports of an unexpected lack of suppressibility by high-dose dexamethasone in patients with Cushing's disease have been largely anecdotal [27, 28] and none have used the extended form of the test. However, Findling and Tyrrell [29] describe 10 patients with the ectopic syndrome (only five of whom had identifiable tumours) and found that four showed 50 per cent suppression of urinary or plasma steroid levels on high-dose dexamethasone.
With the metyrapone test, we found that changes in serum 11-deoxycortisol levels yielded a more useful discrimination than changes in 17-oxogenic steroids or 17-oxosteroids, as was also noted by Perry et al. [30] , though the difference between the mean percentage responses of 11-deoxycortisol in our two groups was not quite significant (p = 0.06). Alternatively, it is noted that the highest response of 11-deoxycortisol in the ectopic group was less than 3-fold, while 11 of the 16 patients with Cushing's disease had a > 3-fold rise. Howlett et al. [3] found an increment of 100 per cent or more in urine 17-oxogenic steroids over basal levels in 64 per cent of their patients with Cushing's disease compared with 50 per cent of those with the ectopic syndrome; our findings are in agreement with this. They found that serum 11-deoxycortisol increments peaked at 24 hours in all cases, and the responses (as measured by absolute values) seen in the three ectopic patients studied were entirely within the range seen in their Cushing's disease group; we also found an overlap in absolute values reached by the two groups, but when the response was assessed by percentage increase in 11-deoxycortisol, there was reasonably good discrimination between the two groups.
When the responses to both dexamethasone and to metyrapone were considered together, we obtained a powerful discrimination: among the 19 patients with Cushing's disease, all except one (Patient 16) showed either suppression in response to dexamethasone or stimulation in response to metyrapone, whereas only one (Patient D) of the seven ectopic patients responded in this way.
Venous sampling for ACTH gradients was undertaken in three patients in this series, but in no case did this yield information that had not already been obtained by other means. The usefulness of petrosal vein sampling and the corticotrophin-releasing factor test in enhancing the ability to distinguish between Cushing's disease and the ectopic ACTH syndrome was not assessed in this series. Hermus et al. [31] suggest that the diagnostic accuracy of the corticotrophin-releasing factor test is comparable to that of the high-dose dexamethasone test; others have found variable patterns of response which have limited its usefulness in certain situations [32] . In further evaluation of these tests, Grossman et al. [4] showed that either test on its own may give 20-25 per cent misleading results in patients with Cushing's disease, whereas three patients with ectopic ACTH responded appropriately in both tests; in agreement with others [31, 33] they found that the combination of the high-dose dexamethasone test and the corticotrophin-releasing factor test is superior to either test alone. We would suggest that the certainty of diagnosis may be further increased by the additional use of the metyrapone test.
Although radiology was of particular use in ascertaining the site of an ectopic tumour, CT scanning of the pituitary is still insufficiently sensitive to detect or exclude the smaller ACTHsecreting adenomas reliably.
In conclusion we suggest that, provided care is taken in the collection and handling of samples and analyses, the aetiology of ACTH-dependent Cushing's syndrome can usually be established by standard procedures without resorting to invasive procedures. It would now be of interest to ascertain the diagnostic efficiency of the criteria listed in Table 9 from independent series.
